

Remarks/Arguments

Applicants have amended the specification to provide the priority claim. The claims 4-9, 11 and 16 have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. Claims 12-14 have been canceled. Claims 13 and 14 have been rewritten in appropriate U.S. format as new claims 17 and 18, respectively. Support for the new claims can be found in original claims 13 and 14 and on page 88, lines 3-11. It is respectfully submitted no new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any canceled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101346-1P US.

Respectfully submitted,

/Carol A. Loeschorn/

Name: Carol A. Loeschorn
Dated: June 22, 2006
Reg. No.: 35,590
Phone No.: 781-839-4002

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451